Targeting RNA transcription and translation in ovarian cancer cells with pharmacological inhibitor CDKI-73

Oncotarget

Volumn 5, Issue 17, 2014, Pages 7691-7704

  Lam, Frankie ^a   Abbas, Abdullahi Y ^b   Shao, Hao ^b   Teo, Theodosia ^a   Adams, Julian ^a   Li, Peng ^a   Bradshaw, Tracey D ^b   Fischer, Peter M ^b   Walsby, Elisabeth ^c   Pepper, Chris ^c   Chen, Yi ^d   Ding, Jian ^d   Wang, Shudong ^a,b  

^a UNIVERSITY OF SOUTH AUSTRALIA   (Australia)

^b UNIVERSITY OF NOTTINGHAM   (United Kingdom)

^c CARDIFF UNIVERSITY   (United Kingdom)

^d SHANGHAI INSTITUTE OF MATERIA MEDICA   (China)

Author keywords

Apoptosis; CDK9; CGP57380; Drug development; EIF4E; Flavopiridol; Kinase inhibitors; Mnks; PI3K Akt mTOR; Ras Raf MAPK; ShRNA; Transcription; Translation

Indexed keywords

3 [5 FLUORO 4 [4 METHYL 2 (METHYLAMINO)THIAZOL 5 YL]PYRIMIDIN 2 YLAMINO]; CASPASE 3; CASPASE 7; CYTOTOXIC AGENT; FLAVOPIRIDOL; INITIATION FACTOR 4E; MNK1 KINASE; PHOSPHOTRANSFERASE; PROTEIN BCL 2; PROTEIN MCL 1; RNA POLYMERASE II; UNCLASSIFIED DRUG; 3-(5-FLUORO-4-(4-METHYL-2-(METHYLAMINO)THIAZOL-5-YL)PYRIMIDIN-2-YLAMINO)BENZENESULFONAMIDE; ANTINEOPLASTIC AGENT; CDK9 PROTEIN, HUMAN; CYCLIN DEPENDENT KINASE 9; PYRIMIDINE DERIVATIVE; RNA; SULFONAMIDE;

APOPTOSIS; ARTICLE; CANCER CELL CULTURE; CELL KINETICS; CELL SURVIVAL; CELL VIABILITY; CONTROLLED STUDY; DOWN REGULATION; DRUG CYTOTOXICITY; DRUG EFFECT; DRUG STRUCTURE; DRUG TARGETING; ENZYME ACTIVATION; ENZYME ACTIVITY; ENZYME INHIBITION; ENZYME PHOSPHORYLATION; FEMALE; HUMAN; HUMAN CELL; IC50; OVARY CANCER; PROTEIN EXPRESSION; RNA TRANSCRIPTION; RNA TRANSLATION; ANTAGONISTS AND INHIBITORS; DRUG EFFECTS; ENZYMOLOGY; GENETIC TRANSCRIPTION; OVARY TUMOR; PHYSIOLOGY; PROTEIN SYNTHESIS; REAL TIME POLYMERASE CHAIN REACTION; SIGNAL TRANSDUCTION; TUMOR CELL LINE; WESTERN BLOTTING;

ANTINEOPLASTIC AGENTS; APOPTOSIS; BLOTTING, WESTERN; CELL LINE, TUMOR; CYCLIN-DEPENDENT KINASE 9; FEMALE; HUMANS; OVARIAN NEOPLASMS; PROTEIN BIOSYNTHESIS; PYRIMIDINES; REAL-TIME POLYMERASE CHAIN REACTION; RNA; SIGNAL TRANSDUCTION; SULFONAMIDES; TRANSCRIPTION, GENETIC;

EID: 84907485889     PISSN: None     EISSN: 19492553     Source Type: Journal    
DOI: 10.18632/oncotarget.2296     Document Type: Article

References (54)

1. Lapenna S and Giordano A. Cell cycle kinases as therapeutic targets for cancer. Nat Rev Drug Discov. 2009; 8(7):547-566.
2. Shapiro GI. Cyclin-dependent kinase pathways as targets for cancer treatment. J Clin Oncol. 2006; 24(11):1770-1783.
3. Wang S and Fischer PM. Cyclin-dependent kinase 9: a key transcriptional regulator and potential drug target in oncology, virology and cardiology. Trends in pharmacological sciences. 2008; 29(6):302-313.
4. Shiekhattar R, Mermelstein F, Fisher RP, Drapkin R, Dynlacht B, Wessling HC, Morgan DO and Reinberg D. Cdk-activating kinase complex is a component of human transcription factor TFIIH. Nature. 1995; 374(6519):283-287.
5. Fisher RP. Secrets of a double agent: CDK7 in cell-cycle control and transcription. J Cell Sci. 2005; 118(Pt 22):5171-5180.
6. Price DH. P-TEFb, a cyclin-dependent kinase controlling elongation by RNA polymerase II. Molecular and Cellular Biology. 2000; 20(8):2629-2634.
7. Garriga J and Grana X. Cellular control of gene expression by T-type cyclin/CDK9 complexes. Gene. 2004; 337:15-23.
8. Marshall RM and Grana X. Mechanisms controlling CDK9 activity. Front Biosci. 2006; 11:2598-2613.
9. Garriga J, Bhattacharya S, Calbo J, Marshall RM, Truongcao M, Haines DS and Grana X. CDK9 is constitutively expressed throughout the cell cycle, and its steady-state expression is independent of SKP2. Mol Cell Biol. 2003; 23(15):5165-5173.
10. Fischer PM and Gianella-Borradori A. CDK inhibitors in clinical development for the treatment of cancer. Expert Opin Investig Drugs. 2003; 12(6):955-970.
11. Byrd JC, Lin TS, Dalton JT, Wu D, Phelps MA, Fischer B, Moran M, Blum KA, Rovin B, Brooker-McEldowney M, Broering S, Schaaf LJ, Johnson AJ, Lucas DM, Heerema NA, Lozanski G, et al. Flavopiridol administered using a pharmacologically derived schedule is associated with marked clinical efficacy in refractory, genetically high-risk chronic lymphocytic leukemia. Blood. 2007; 109(2):399-404.
12. Christian BA, Grever MR, Byrd JC and Lin TS. Flavopiridol in chronic lymphocytic leukemia: a concise review. Clin Lymphoma Myeloma. 2009; 9 Suppl 3:S179-185.
13. Liu X, Shi S, Lam F, Pepper C, Fischer PM and Wang S. CDKI-71, a novel CDK9 inhibitor, is preferentially cytotoxic to cancer cells compared to flavopiridol. International Journal of Cancer 2012; 130(5):1216-1226.
14. Caracciolo V, Laurenti G, Romano G, Carnevale V, Cimini AM, Crozier-Fitzgerald C, Gentile Warschauer E, Russo G and Giordano A. Flavopiridol induces phosphorylation of AKT in a human glioblastoma cell line, in contrast to siRNA-mediated silencing of Cdk9: Implications for drug design and development. Cell Cycle. 2012; 11(6):1202-1216.
15. Chen R, Keating MJ, Gandhi V and Plunkett W. Transcription inhibition by flavopiridol: mechanism of chronic lymphocytic leukemia cell death. Blood. 2005; 106(7):2513-2519.
16. Meijer L and Raymond E. Roscovitine and Other Purines as Kinase Inhibitors. From Starfish Oocytes to Clinical Trials. Accounts of Chemical Research. 2003; 36(6):417-425.
17. Wang S, McClue SJ, Ferguson JR, Hull JD, Stokes S, Parsons S, Westwood R and Fischer PM. Synthesis and configuration of the cyclin-dependent kinase inhibitor roscovitine and its enantiomer. Tetrahedron: Asymmetry. 2001; 12(20):2891-2894.
18. McClue SJ, Blake D, Clarke R, Cowan A, Cummings L, Fischer PM, MacKenzie M, Melville J, Stewart K, Wang S, Zhelev N, Zheleva D and Lane DP. In vitro and in vivo antitumor properties of the cyclin dependent kinase inhibitor CYC202 (R-roscovitine). International journal of cancer Journal international du cancer. 2002; 102(5):463-468.
19. Lacrima K, Valentini A, Lambertini C, Taborelli M, Rinaldi A, Zucca E, Catapano C, Cavalli F, Gianella-Borradori A, Maccallum DE and Bertoni F. In vitro activity of cyclin-dependent kinase inhibitor CYC202 (Seliciclib, R-roscovitine) in mantle cell lymphomas. Ann Oncol. 2005; 16(7):1169-1176.
20. MacCallum DE, Melville J, Frame S, Watt K, Anderson S, Gianella-Borradori A, Lane DP and Green SR. Seliciclib (CYC202, R-Roscovitine) induces cell death in multiple myeloma cells by inhibition of RNA polymerase II-dependent transcription and down-regulation of Mcl-1. Cancer Res. 2005; 65(12):5399-5407.
21. Anderson M, Andrews DM, Barker AJ, Brassington CA, Breed J, Byth KF, Culshaw JD, Finlay MR, Fisher E, McMiken HH, Green CP, Heaton DW, Nash IA, Newcombe NJ, Oakes SE, Pauptit RA, et al. Imidazoles: SAR and development of a potent class of cyclin-dependent kinase inhibitors. Bioorg Med Chem Lett. 2008; 18(20):5487-5492.
22. Chu XJ, DePinto W, Bartkovitz D, So SS, Vu BT, Packman K, Lukacs C, Ding Q, Jiang N, Wang K, Goelzer P, Yin X, Smith MA, Higgins BX, Chen Y, Xiang Q, et al. Discovery of [4-Amino-2-(1-methanesulfonylpiperidin-4-ylamino)pyrimidin-5-yl](2,3-diflu oro-6-methoxyphenyl)methanone (R547), a potent and selective cyclin-dependent kinase inhibitor with significant in vivo antitumor activity. J Med Chem. 2006; 49(22):6549-6560.
23. DePinto W, Chu XJ, Yin X, Smith M, Packman K, Goelzer P, Lovey A, Chen Y, Qian H, Hamid R, Xiang Q, Tovar C, Blain R, Nevins T, Higgins B, Luistro L, et al. In vitro and in vivo activity of R547: a potent and selective cyclin-dependent kinase inhibitor currently in phase I clinical trials. Mol Cancer Ther. 2006; 5(11):2644-2658.
24. Wyatt PG, Woodhead AJ, Berdini V, Boulstridge JA, Carr MG, Cross DM, Davis DJ, Devine LA, Early TR, Feltell RE, Lewis EJ, McMenamin RL, Navarro EF, O'Brien MA, O'Reilly M, Reule M, et al. Identification of N-(4-piperidinyl)-4-(2,6-dichlorobenzoylamino)-1H-pyrazole-3-carboxamide (AT7519), a novel cyclin dependent kinase inhibitor using fragment-based X-ray crystallography and structure based drug design. J Med Chem. 2008; 51(16):4986-4999.
25. Fry DW, Harvey PJ, Keller PR, Elliott WL, Meade M, Trachet E, Albassam M, Zheng X, Leopold WR, Pryer NK and Toogood PL. Specific inhibition of cyclin-dependent kinase 4/6 by PD 0332991 and associated antitumor activity in human tumor xenografts. Molecular Cancer Therapeutics. 2004; 3(11):1427-1438.
26. Finn RS, Dering J, Conklin D, Kalous O, Cohen DJ, Desai AJ, Ginther C, Atefi M, Chen I, Fowst C, Los G and Slamon DJ. PD 0332991, a selective cyclin D kinase 4/6 inhibitor, preferentially inhibits proliferation of luminal estrogen receptor-positive human breast cancer cell lines in vitro. Breast Cancer Res. 2009; 11(5):R77.
27. Dickson MA, Tap WD, Keohan ML, D'Angelo SP, Gounder MM, Antonescu CR, Landa J, Qin LX, Rathbone DD, Condy MM, Ustoyev Y, Crago AM, Singer S and Schwartz GK. Phase II trial of the CDK4 inhibitor PD0332991 in patients with advanced CDK4-amplified well-differentiated or dedifferentiated liposarcoma. J Clin Oncol. 2013; 31(16):2024-2028.
28. Diab S, Kumarasiri M, Yu M, Teo T, Proud C, Milne R and Wang S. MAP kinase-interacting kinases-emerging targets against cancer. Chem Biol. 2014; 21(4):441-452.
29. Hou J, Lam F, Proud C and Wang S. Targeting Mnks for cancer therapy. Oncotarget. 2012; 3(2):118-131.
30. Ueda T, Watanabe-Fukunaga R, Fukuyama H, Nagata S and Fukunaga R. Mnk2 and Mnk1 are essential for constitutive and inducible phosphorylation of eukaryotic initiation factor 4E but not for cell growth or development. Mol Cell Biol. 2004; 24(15):6539-6549.
31. Ueda T, Sasaki M, Elia AJ, Chio, II, Hamada K, Fukunaga R and Mak TW. Combined deficiency for MAP kinase-interacting kinase 1 and 2 (Mnk1 and Mnk2) delays tumor development. Proc Natl Acad Sci U S A. 2010; 107(32):13984-13990.
32. Walsby E, Pratt G, Shao H, Abbas AY, Fischer PM, Bradshaw TD, Brennan P, Fegan C, Wang S and Pepper C. A novel Cdk9 inhibitor preferentially targets tumor cells and synergizes with fludarabine. 2013;2(5),375-385
33. Shao H, Shi S, Huang S, Hole AJ, Abbas AY, Baumli S, Liu X, Lam F, Foley DW, Fischer PM, Noble M, Endicott JA, Pepper C and Wang S. Substituted 4-(thiazol-5-yl)-2-(phenylamino)pyrimidines are highly active CDK9 inhibitors: synthesis, X-ray crystal structures, structure-activity relationship, and anticancer activities. Journal of medicinal chemistry. 2013; 56(3):640-659.
34. Hole AJ, Baumli S, Shao H, Shi S, Huang S, Pepper C, Fischer PM, Wang S, Endicott JA and Noble ME. Comparative structural and functional studies of 4-(thiazol-5-yl)-2-(phenylamino)pyrimidine-5-carbonitrile CDK9 inhibitors suggest the basis for isotype selectivity. Journal of medicinal chemistry. 2013; 56(3):660-670.
35. Waskiewicz AJ, Johnson JC, Penn B, Mahalingam M, Kimball SR and Cooper JA. Phosphorylation of the cap-binding protein eukaryotic translation initiation factor 4E by protein kinase Mnk1 in vivo. Mol Cell Biol. 1999; 19(3):1871-1880.
36. Wang S, Griffiths G, Midgley CA, Barnett AL, Cooper M, Grabarek J, Ingram L, Jackson W, Kontopidis G, McClue SJ, McInnes C, McLachlan J, Meades C, Mezna M, Stuart I, Thomas MP, et al. Discovery and characterization of 2-anilino-4-(thiazol-5-yl)pyrimidine transcriptional CDK inhibitors as anticancer agents. Chemistry & biology. 2010; 17(10):1111-1121.
37. Hay N. Mnk earmarks eIF4E for cancer therapy. Proc Natl Acad Sci U S A. 2010; 107(32):13975-13976.
38. Diab S, Teo T, Kumarasiri M, Li P, Yu M, Lam F, Basnet SK, Sykes MJ, Albrecht H, Milne R and Wang S. Discovery of 5-(2-(phenylamino)pyrimidin-4-yl)thiazol-2(3H)-one derivatives as potent Mnk2 inhibitors: synthesis, SAR analysis and biological evaluation. ChemMedChem. 2014; 9(5):962-972.
39. Buxade M, Parra-Palau JL and Proud CG. The Mnks: MAP kinase-interacting kinases (MAP kinase signal-integrating kinases). Front Biosci. 2008; 13:5359-5373.
40. Bain J, Plater L, Elliott M, Shpiro N, Hastie CJ, McLauchlan H, Klevernic I, Arthur JS, Alessi DR and Cohen P. The selectivity of protein kinase inhibitors: a further update. The Biochemical journal. 2007; 408(3):297-315.
41. Konicek BW, Stephens JR, McNulty AM, Robichaud N, Peery RB, Dumstorf CA, Dowless MS, Iversen PW, Parsons S, Ellis KE, McCann DJ, Pelletier J, Furic L, Yingling JM, Stancato LF, Sonenberg N, et al. Therapeutic inhibition of MAP kinase interacting kinase blocks eukaryotic initiation factor 4E phosphorylation and suppresses outgrowth of experimental lung metastases. Cancer Res. 2011; 71(5):1849-1857.
42. Manohar SM, Rathos MJ, Sonawane V, Rao SV and Joshi KS. Cyclin-dependent kinase inhibitor, P276-00 induces apoptosis in multiple myeloma cells by inhibition of Cdk9-T1 and RNA polymerase II-dependent transcription. Leuk Res. 2011; 35(6):821-830.
43. Muller P, Ruckova E, Halada P, Coates PJ, Hrstka R, Lane DP and Vojtesek B. C-terminal phosphorylation of Hsp70 and Hsp90 regulates alternate binding to co-chaperones CHIP and HOP to determine cellular protein folding/degradation balances. Oncogene. 2013; 32(25):3101-3110.
44. O'Keeffe B, Fong Y, Chen D, Zhou S and Zhou Q. Requirement for a kinase-specific chaperone pathway in the production of a Cdk9/cyclin T1 heterodimer responsible for P-TEFb-mediated tat stimulation of HIV-1 transcription. J Biol Chem. 2000; 275(1):279-287.
45. Demidenko ZN and Blagosklonny MV. Flavopiridol induces p53 via initial inhibition of Mdm2 and p21 and, independently of p53, sensitizes apoptosis-reluctant cells to tumor necrosis factor. Cancer Res. 2004; 64(10):3653-3660.
46. Stewart DP, Koss B, Bathina M, Perciavalle RM, Bisanz K and Opferman JT. Ubiquitin-independent degradation of antiapoptotic MCL-1. Mol Cell Biol. 2010; 30(12):3099-3110.
47. Warr MR and Shore GC. Unique biology of Mcl-1: therapeutic opportunities in cancer. Curr Mol Med. 2008; 8(2):138-147.
48. Quinn BA, Dash R, Azab B, Sarkar S, Das SK, Kumar S, Oyesanya RA, Dasgupta S, Dent P, Grant S, Rahmani M, Curiel DT, Dmitriev I, Hedvat M, Wei J, Wu B, et al. Targeting Mcl-1 for the therapy of cancer. Expert Opin Investig Drugs. 2011; 20(10):1397-1411.
49. Gores GJ and Kaufmann SH. Selectively targeting Mcl-1 for the treatment of acute myelogenous leukemia and solid tumors. Genes Dev. 2012; 26(4):305-311.
50. Wheater MJ, Johnson PW and Blaydes JP. The role of MNK proteins and eIF4E phosphorylation in breast cancer cell proliferation and survival. Cancer Biol Ther. 2010; 10(7):728-735.
51. Iglesias-Serret D, Pique M, Gil J, Pons G and Lopez JM. Transcriptional and translational control of Mcl-1 during apoptosis. Archives of Biochemistry and Biophysics. 2003; 417(2):141-152.
52. Gottesman MM, Fojo T and Bates SE. Multidrug resistance in cancer: role of ATP-dependent transporters. Nat Rev Cancer. 2002; 2(1):48-58.
53. Wang S, Meades C, Wood G, Osnowski A, Anderson S, Yuill R, Thomas M, Mezna M, Jackson W, Midgley C, Griffiths G, Fleming I, Green S, McNae I, Wu SY, McInnes C, et al. 2-Anilino-4-(thiazol-5-yl)pyrimidine CDK inhibitors: synthesis, SAR analysis, X-ray crystallography, and biological activity. Journal of medicinal chemistry. 2004; 47(7):1662-1675.
54. Rustandi RR, Loughney JW, Hamm M, Hamm C, Lancaster C, Mach A and Ha S. Qualitative and quantitative evaluation of Simon, a new CE-based automated Western blot system as applied to vaccine development. Electrophoresis. 2012; 33(17):2790-2797.